Pharmacogenetics and drug-induced arrhythmias

Cardiovascular Research

Volumn 50, Issue 2, 2001, Pages 224-231

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DISPOSITION; DRUG INDUCED DISEASE; DRUG TARGETING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; HUMANS; LONG QT SYNDROME; PHARMACOGENETICS;

EID: 0035040834     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00302-3     Document Type: Review

References (53)

1. Prolonged apnea following injection of succinylcholine
2. Genetic control of isoniazid metabolism in man
3. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome
4. Polymorphic hydroxylation of debrisoquine in man
5. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
6. Molecular mechanisms of genetic polymorphisms of drug metabolism
7. Ultrarapid hydroxylation of debrisoquine in a Swedish population: Analysis of the molecular genetic basis
8. Pharmacogenetics and the practice of medicine
9. Science, medicine, and the future: Pharmacogenetics
10. Pharmacogenomics: Translating functional genomics into rational therapeutics
11. The geneticist's approach to complex disease
12. Point of view: Acquired long QT syndromes and the risk of proarrhythmia
13. Kr potassium channel
14. Kr potassium channels with HERG and is associated with cardiac arrhythmia
15. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
16. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome
17. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
18. KCNE1 polymorphism confers risk of drug-induced long QT syndrome by altering kinetic properties of IKs potassium channels
19. Cinchona derivatives in the treatment of heart disorders
20. Quinidine syncope paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias
21. La tachycardie ventriculaire à deux foyers opposés variables
22. Torsades de pointes as a manifestation of mexiletine toxicity
23. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome
24. Class III antiarrhythmic agents have a lot of potential, but a long way to go: Reduced effectiveness and dangers of reverse use dependence
25. Kr: Implications for torsades de pointes and reverse use-dependence
26. Mechanism of the cardiotoxic actions of terfenadine
27. Cisapride and fatal arrhythmia
28. Torsades de pointes with an antihistamine metabolite potassium channel blockade with desmethylastemizole
29. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype
30. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current
31. Torsades de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients
32. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care
33. + currents
34. + current in cardiac cells
35. A sensitive mechanism for cation modulation of potassium current
36. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
37. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations
38. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm
39. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter. A prospective study
40. Taking the idio out of idiosyncratic - Predicting torsades de pointes
41. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
42. ST segment elevation in the right precordial leads induced with class Ic antiarrhythmic drugs: Insight into the mechanism of Brugada syndrome
43. ST segment elevation induced by class Ic antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia
44. Drug-induced J point elevation: A marker for genetic risk of sudden death or ECG curiosity?
45. The Brugada syndrome: Clinical, electrophysiologic and genetic aspects
46. 'Brugada' syndrome: Clinical data and suggested pathophysiological mechanism
47. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 re-entry?
48. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia. Role of the transient outward current
49. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma
50. The Ile164 beta(2)-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
51. Beta(1)-adrenoceptor gene variations: A role in idiopathic dilated cardiomyopathy?
52. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction